Ivosidenib as Post-HSCT Maintenance for AML

Summary

This is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HCT).

Timeline

Start

2026-01-16

Primary completion

2028-01-01

Completion

2030-01-01

Drugs

Indications